DIH Holdings US Stock Price, News & Analysis

DIH (NASDAQ: DHAI), a provider of advanced robotic rehabilitation devices, has announced the pricing of a $4.6 million public offering. The offering consists of 5,937,100 units priced at $0.7832 per unit. Each unit includes one share of Class A common stock (or pre-funded warrant) and one Class A warrant.

The Class A warrants will have an exercise price of $0.7832 per share, will be immediately exercisable, and will expire after five years. The offering is expected to close around February 3, 2025. Maxim Group is serving as the sole placement agent.

The company plans to use the net proceeds for capital expenditures, working capital, and general corporate purposes. The offering is being made pursuant to an effective registration statement on Form S-1.

DIH (NASDAQ:DHAI) has announced a strategic partnership with Nobis Rehabilitation Partners to integrate Andago®, an overground gait and balance training device, into all of Nobis' newly established hospitals. Nobis, founded in 2018, currently manages over 17 inpatient rehabilitation hospitals across the US, with more in development.

The partnership aims to enhance rehabilitation services by implementing advanced technology that ensures both patient and staff safety. Andago® provides intelligent dynamic body weight support for walking and standing practice, particularly beneficial for patients with stroke, spinal cord injury, brain injury, and other neurologic and orthopedic conditions.

This collaboration combines DIH's technological expertise with Nobis' clinical experience to improve care quality and expand treatment accessibility. The integration of Andago® devices aligns with both companies' goals of advancing rehabilitation therapy standards and delivering quality-driven results.

DIH (NASDAQ:DHAI) has appointed Shepherd Center as a DIH Center of Excellence, establishing a strategic partnership to enhance rehabilitation outcomes. Shepherd Center, located in Atlanta, Georgia, specializes in neurorehabilitation and utilizes DIH's advanced robotic devices including Erigo®Pro, Lokomat®Pro, C-Mill VR+, and the Armeo® product family.

The partnership aims to showcase best practices in rehabilitation robotics and contribute to the development of advanced rehabilitation technologies. Shepherd Center's expertise focuses on complex conditions including spinal cord and brain injuries, multi-trauma, traumatic amputations, stroke, multiple sclerosis, and pain.

DIH (NASDAQ:DHAI) has designated Sheltering Arms Institute, a collaboration with VCU Health, as a DIH Center of Excellence. The institute, located in Richmond, Virginia, utilizes DIH's Total Solution, including Erigo®Pro, Lokomat®Pro, Andago V2.0®, RYSEN, C-Mill VR+, Armeo®Power, and Armeo®Spring to provide personalized rehabilitation care. This partnership strengthens DIH's presence among top-tier healthcare providers and recognizes Sheltering Arms Institute's role in showcasing best practices in rehabilitation robotics. The institute will contribute to developing advanced rehabilitation technologies and implementing them across North America.

DIH (NASDAQ:DHAI) reported Q2 2025 financial results with revenue of $18.2 million, up 39% year-over-year. Device revenue grew 49% to $15.0 million, while service revenue remained flat at $2.7 million. The company saw significant growth in EMEA (72%) and Americas (20%). Gross margin improved to 52.6%, and income before taxes reached $0.1 million.

The company restated Q1 2025 revenue to $17.0 million (30% YoY growth) from previously reported $16.2 million. DIH revised its fiscal year 2025 revenue guidance to $60-67 million. The restatement was due to timing adjustments for two device sales in June 2024.

DIH (NASDAQ:DHAI) has appointed Dietmar Dold as Chief Operating Officer, effective immediately. With over 25 years of operating experience, Dold will lead DIH's multi-group operating strategy, focusing on optimizing manufacturing, sourcing initiatives, and building operations teams. Previously, he served as CEO at Videojet Technologies and held positions at KPMG, Condair Group, Sonova, and Roche Diagnostics. At Air New Zealand, he contributed to tripling the company's value over three years. Dold holds a computer science degree, an Executive MBA, and a Board of Director Diploma from IMD.

DIH Holding US, Inc. (NASDAQ:DHAI) has announced the formation of its Scientific Advisory Board (SAB). The SAB will advise DIH on technical and scientific matters, offer insights into industry trends, provide feedback on product development, and advise on research plans. The board comprises leading scientists and clinicians with expertise in rehabilitation technologies, biomechanics, neuromuscular control, and related fields.

The inaugural SAB members include:

• Paolo Bonato, Ph.D. - Director of Motion Analysis Laboratory at Spaulding Rehabilitation Hospital
• Jonathan Dingwell, Ph.D. - Professor of Kinesiology at Pennsylvania State University
• Alberto Esquenazi, MD - Chief Medical Officer at MossRehab
• Kenneth Meijer, Ph.D. - Professor of Human Movement Sciences at Maastricht University
• Giovanni Morone, MD - Assistant Professor at University of L'Aquila
• David Reinkensmeyer, Ph.D. - Professor at University of California at Irvine
• Robert Riener, Ph.D. - Professor at ETH Zürich
• Melvyn Roerdink, Ph.D. - Associate Professor at Vrije Universiteit Amsterdam

The inaugural meeting took place on September 23rd in Switzerland.

DIH Holding US, Inc. (NASDAQ:DHAI) has appointed Haapsalu Neurological Rehabilitation Center (HNRC) in Estonia as its latest DIH Center of Excellence. HNRC, founded in 1958, is the first such center in the Baltics Region. The center utilizes DIH's advanced robotic rehabilitation technologies, including Hocoma's Lokomat®Pro, Erigo® devices, and Armeo®Spring for comprehensive patient care.

HNRC offers inpatient and outpatient rehabilitation services for children and adults with neurological disorders, combining innovative technologies with clinical expertise. This appointment recognizes HNRC's commitment to integrating cutting-edge solutions into patient care and setting new standards for neurorehabilitation in the region.

DIH Holding US, Inc. (NASDAQ:DHAI) announced financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:

• Revenue of $16.2 million, up 24% year-over-year
• Device revenue of $12.3 million (+18%) and service revenue of $3.5 million (+49%)
• 54% revenue growth in both EMEA and Americas
• Gross Margin improved to 53.5%, up 12 percentage points
• Net loss reduced to $0.6 million, a $2.3 million improvement

DIH reiterated its FY2025 revenue guidance of $74-$77 million, representing 15-20% growth. The company reported strong performance in strategic markets and improved operational efficiency. Cash and cash equivalents totaled $2.7 million as of June 30, 2024.